Tebon Securities has released a research report stating that the biomedical industry chain exhibits a "demand recovery → life sciences upstream → CXO" step-by-step transmission pattern. AIDD, as a new variable, reverses the pull on life sciences upstream demand through a dry-wet experiment closed loop, thereby transmitting step by step to the CXO sector. As time progresses and new technologies continue to emerge, AIDD is expected to empower the entire pharmaceutical industry, and the firm believes AIDD has a promising future. The main points of Tebon Securities are as follows:
On the CXO demand side, the core variables suppressing the sector are reversing. Global biomedical investment and financing are improving at the margin, and overseas pharmaceutical companies' R&D budgets and outsourcing penetration rates are rising overall; orders precede revenue, and revenue precedes profit, with leading companies' orders already recovering first. On the supply side, the industry landscape is shifting toward clearance, previously excessive capacity has been gradually depleted, and industry CAPEX has begun a new round of expansion. Looking ahead to 2027 and beyond, the firm believes the CXO industry stands at a new demand starting point. As new molecules and other factors impose ever-higher requirements on process development and trial design capabilities, China's CXO industry is expected to maintain international competitiveness by leveraging the "engineer dividend" and accumulating early-stage R&D experience. Recommended stocks to watch: WuXi AppTec, WuXi Biologics, WuXi XDC, Pharmaron, Asymchem, Haoyuan Pharma, Tigermed, Medicilon, Joinn Laboratories, and Apeloa Pharmaceutical.
For life sciences upstream, the firm is bullish on the sector returning to an upward trajectory. As the total value of domestic innovative drug BD continues to rise, coupled with the sustained development of domestic basic research, the firm expects future core drivers to come from a recovery in scientific research demand and a rebound in innovative drug R&D investment; meanwhile, under the AIDD dry-wet closed loop, AI批量 outputs candidate molecules, further driving orders for high-throughput validation consumables such as proteins, gene synthesis, culture media, and model animals, constituting an important incremental source of sector elasticity. Domestic substitution is timely, and as the domestic substitution rate continues to rise in the future, the firm expects the overall market size of life sciences upstream to see further growth. Recommended stocks to watch: GenScript Biotech, ACROBiosystems, Haoyuan Pharma, Bide Pharmatech, GemPharmatech, Biocytogen, and Novoprotein.
Bullish on the long-term development of the AIDD industry. The AIDD industry is still in its early stages of development with large potential market space. Generative AI and large model technologies are driving drug design to leap from "assisted screening" to "de novo generation," and national policies are continuously advancing the development of AI4S. As time progresses and new technologies continue to emerge, AIDD is expected to empower the entire pharmaceutical industry, and the firm believes AIDD has a promising future. Recommended stocks to watch: Insilico Medicine, XtalPi Holdings, and JITAI Technology.
Risk warnings: policy changes, geopolitical disruptions, clinical failures, BD termination risks, investment tightening risks, etc.
Comments